Current strategies in the treatment of non-muscle-invasive bladder cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 8, 2012, Pages 1097-1106

  Oosterlinck, Willem ^a   Decaestecker, Karel ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

bacillus Calmette Gu rin; epirubicine; mitomycine C; non muscle invasive bladder cancer; review; urothelial neoplasm

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; INTERFERON; MITOMYCIN C;

BLADDER BIOPSY; BLADDER IRRIGATION; BLADDER PAPILLOMA; BLADDER TUMOR; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CYSTITIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG TREATMENT FAILURE; ENDOCYTOSCOPY; EVIDENCE BASED MEDICINE; FLUORESCENCE IMAGING; HUMAN; META ANALYSIS (TOPIC); NON MUSCLE INVASIVE BLADDER CANCER; PHOTODYNAMIC THERAPY; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROSTATE BIOPSY; REOPERATION; REVIEW; RISK FACTOR; SEPSIS; TAT1 PAPILLARY BLADDER TUMOR; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR BIOPSY;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; BIOPSY; CARCINOMA IN SITU; CYSTOSCOPY; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PROSTATE; TREATMENT OUTCOME; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 84867034078     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.87     Document Type: Review

References (93)

1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J. Urol. 27(3), 289-293 (2009).
2. Babjuk M, Oosterlinck W, Sylvester R et al.; European Association of Urology (EAU). EAU guidelines on non-muscleinvasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol. 59(6), 997-1008 (2011).
3. Brausi M, Collette L, Kurth K et al.; EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol. 41(5), 523-531 (2002).
4. Mariappan P, Finney SM, Head E et al.; Edinburgh Urological Cancer Group. Good quality white-light transurethral resection of bladder tumours (GQWLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int. 109(11), 1666-1673 (2012).
5. Mariappan P, Zachou A, Grigor KM; Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur. Urol. 57(5), 843-849 (2010).
6. van der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, de Balincourt C. Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur. Urol. 35(4), 267-271 (1999).
7. Palou J, Sylvester RJ, Rodriguez FO et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur. Urol. 62(1), 118-125 (2012).
8. Kausch I, Sommerauer M, Montorsi F et al. Photodynamic diagnosis in non-muscleinvasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur. Urol. 57(4), 595-606 (2010).
9. Ray ER, Chatterton K, Khan MS et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guèrin. BJU Int. 105(6), 789-794 (2010).
10. Draga RO, Grimbergen MC, Kok ET, Jonges TN, van Swol CF, Bosch JL. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guèrin immunotherapy and mitomycin C intravesical therapy. Eur. Urol. 57(4), 655-660 (2010).
11. Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscleinvasive bladder cancer (NMIBC)?. BJU Int. 109(4), 549-556 (2012).
12. Schumacher MC, Holmäng S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP. Transurethral resection of non-muscleinvasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur. Urol. 57(2), 293-299 (2010).
13. Stenzl A, Burger M, Fradet Y et al. Hexaminolevulinate-guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer. J. Urol. 184(5), 1907-1913 (2010).
14. Witjes JA, Redorta JP, Jacqmin D et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur. Urol. 57(4), 607-614 (2010).
15. Cauberg EC, Mamoulakis C, de la Rosette JJ, de Reijke TM. Narrow-band imagingassisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate. World J. Urol. 29(4), 503-509 (2011).
16. Shen YJ, Zhu YP, Ye DW et al. Narrowband imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a 'second look' matters?. Int. Urol. Nephrol. 44(2), 451-457 (2012).
17. Kulkarni GS, Hakenberg OW, Gschwend JE et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur. Urol. 57(1), 60-70 (2010).
18. Fritsche HM, Burger M, Svatek RS et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur. Urol. 57(2), 300-309 (2010).
19. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J. Urol. 170(2 Pt. 1), 433-437 (2003).
20. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol. 175(5), 1641-1644 (2006).
21. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and diseasespecific survival: a prospective randomised clinical trial. Eur. Urol. 58(2), 185-190 (2010).
22. Dalbagni G, Vora K, Kaag M et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur. Urol. 56(6), 903-910 (2009).
23. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49(3), 466-5; discussion 475 (2006).
24. Jancke G, Rosell J, Jahnson S. Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder. Scand. J. Urol. Nephrol. 45(6), 388-392 (2011).
25. van Rhijn BW, Zuiverloon TC, Vis AN et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur. Urol. 58(3), 433-441 (2010).
26. Fernandez-Gomez J, Madero R, Solsona E et al. Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J. Urol. 182(5), 2195-2203 (2009).
27. Fernandez-Gomez J, Madero R, Solsona E et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur. Urol. 60(3), 423-430 (2011).
28. Chade DC, Shariat SF, Godoy G et al. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J. Urol. 184(1), 74-80 (2010).
29. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high-risk nonmuscle invasive bladder cancer. Urol. Oncol. 27(2), 155-159 (2009).
30. Zuiverloon TC, Nieuweboer AJ, Vèkony H, Kirkels WJ, Bangma CH, Zwarthoff EC. Markers predicting response to bacillus Calmette-Guèrin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur. Urol. 61(1), 128-145 (2012).
31. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 171(6 Pt 1), 2186-90, quiz 2435 (2004).
32. De Nunzio C, Carbone A, Albisinni S et al. Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. World J. Urol. 29(4), 517-521 (2011).
33. Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmäng S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J. Urol. 179(1), 101-105; discussion 105 (2008).
34. Gudjónsson S, Adell L, Merdasa F et al. Should all patients with non-muscleinvasive bladder cancer receive early intravesical chemotherapy after transurethral resection?. The results of a prospective randomised multicentre study. Eur. Urol. 55(4), 773-780 (2009).
35. Jung SJ, Chang HS, Park CH, Kim CI, Kim BH. Effectiveness of an immediate mitomycin C instillation in patients with superficial bladder cancer receiving periodic mitomycin C instillation. Korean J. Urol. 52(5), 323-326 (2011).
36. Kaasinen E, Rintala E, Hellström P et al.; FinnBladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur. Urol. 42(2), 167-174 (2002).
37. Badalato GM, Hruby G, Razmjoo M, McKiernan JM. Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG?. Can. J. Urol. 18(5), 5890-5895 (2011).
38. Chamie K, Saigal CS, Lai J et al.; Urologic Diseases in America Project. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 117(23), 5392-5401 (2011).
39. Hendricksen K, Witjes WP, Idema JG et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur. Urol. 53(5), 984-991 (2008).
40. O'Brien T, Ray E, Singh R, Coker B, Beard R; British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur. Urol. 60(4), 703-710 (2011).
41. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 171 (6 Pt 1), 2186-2190, quiz 2435 (2004).
42. Böhle A, Leyh H, Frei C et al.; S274 Study Group. Single postoperative instillation of gemcitabine in patients with non-muscleinvasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled Phase III multicentre study. Eur. Urol. 56(3), 495-503 (2009).
43. Onishi T, Sasaki T, Hoshina A, Yabana T. Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor. Anticancer Res. 31(4), 1471-1474 (2011).
44. Engeler DS, Wyler S, Neyer M, Hobi C, Müller J, Schmid HP. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases. Scand. J. Urol. Nephrol. 42(6), 522-527 (2008).
45. Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J. Urol. 156(6), 1934-40, discussion 1940 (1996).
46. Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J. Clin. Epidemiol. 53(7), 676-680 (2000).
47. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 21(1B), 765-769 (2001).
48. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscleinvasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur. Urol. 53(4), 709-719 (2008).
49. Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst. Rev. 1, CD009294 (2012).
50. Au JL, Badalament RA, Wientjes MG et al.; International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized Phase III trial. J. Natl. Cancer Inst. 93(8), 597-604 (2001).
51. Kuroda M, Niijima T, Kotake T, Akaza H, Hinotsu S; 6th Trial of the Japanese Urological Cancer Research Group. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer-The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40ml, 30 mg/40ml, 40 mg/40ml. Eur. Urol. 45(5), 600-605 (2004).
52. Lammers RJ, Witjes JA, Inman BA et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur. Urol. 60(1), 81-93 (2011).
53. Colombo R, Salonia A, Leib Z, Pavone?Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparingthermochemotherapy with mitomycin-C alone as adjuvant treatment for nonmuscle-invasive bladder cancer (NMIBC). BJU Int. 107(6), 912-918 (2011).
54. Kalsi J, Harland SJ, Feneley MR. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma. Expert Opin. Drug Deliv. 5(1), 137-145 (2008).
55. Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 7(1), 43-51 (2006).
56. Di Stasi SM, Valenti M, Verri C et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 12(9), 871-879 (2011).
57. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guèrin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 93(4), 485-490 (2004).
58. Shelley MD, Kynaston H, Court J et al. A systematic review of intravesical bacillus Calmette-Guèrin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 88(3), 209-216 (2001).
59. Han RF, Pan JG. Can intravesical bacillus Calmette-Guèrin reduce recurrence in patients with superficial bladder cancer?. A meta-analysis of randomized trials. Urology 67(6), 1216-1223 (2006).
60. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 169(1), 90-95 (2003).
61. Shang PF, Kwong J, Wang ZP et al. Intravesical bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst. Rev. 5, CD006885 (2011).
62. Duchek M, Johansson R, Jahnson S et al.; Members of the Urothelial Cancer Group of the Nordic Association of Urology. Bacillus Calmette-Guèrin is superior to a combination of epirubicin and interferon-?2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur. Urol. 57(1), 25-31 (2010).
63. Järvinen R, Kaasinen E, Sankila A, Rintala E; FinnBladder Group. Long-term efficacy of maintenance bacillus Calmette-Guèrin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur. Urol. 56(2), 260-265 (2009).
64. Sylvester RJ, Brausi MA, Kirkels WJ et al.; EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guèrin, and bacillus Calmette-Guèrin plus isoniazid in patients with intermediate-and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur. Urol. 57(5), 766-773 (2010).
65. Hinotsu S, Akaza H, Naito S et al. Maintenance therapy with bacillus Calmette-Guèrin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int. 108(2), 187-195 (2011).
66. Malmström PU, Sylvester RJ, Crawford DE et al. An individual patient data metaanalysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guèrin for non-muscle-invasive bladder cancer. Eur. Urol. 56(2), 247-256 (2009).
67. Böhle A, Bock PR. Intravesical bacille Calmette-Guèrin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63(4), 682-6; discussion 686 (2004).
68. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168(5), 1964-1970 (2002).
69. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol. 174(1), 86-91; discussion 91 (2005).
70. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163(4), 1124-1129 (2000).
71. Herr HW, Dalbagni G, Donat SM. Bacillus Calmette-Guèrin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur. Urol. 60(1), 32-36 (2011).
72. Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E et al.; Club Urológico Español de Tratamiento Oncológico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?. Results of a prospective randomized trial. J. Urol. 174(4 Pt 1), 1242-1247 (2005).
73. Ojea A, Nogueira JL, Solsona E et al.; CUETO Group (Club Urológico Español De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur. Urol. 52(5), 1398-1406 (2007).
74. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur. Urol. 44(4), 429-434 (2003).
75. Losa A, Hurle R, Lembo A. Low-dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J. Urol. 163(1), 68-71; discussion 71 (2000).
76. Griffiths TR, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J. Urol. 167(6), 2408-2412 (2002).
77. Jakse G, Hall R, Bono A et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group Phase II protocol 30861. Eur. Urol. 40(2), 144-150 (2001).
78. Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M. Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder. International Journal of Urology 15(4), 309-313 (2008).
79. Gofrit ON, Pode D, Pizov G et al. The natural history of bladder carcinoma in situafter initial response to bacillus Calmette-Gúerin immunotherapy. Urol. Oncol. 27(3), 258-262 (2009).
80. van der Meijden AP, Sylvester R, Oosterlinck W et al.; for the EAU Working Party on Non Muscle Invasive Bladder Cancer. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur. Urol. 48(3), 363-371 (2005).
81. Oosterlinck W, Kirkali Z, Sylvester R et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guèrin and with bacillus Calmette-Guèrin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genitourinary group randomized Phase 2 trial (30993). Eur. Urol. 59(3), 438-446 (2011).
82. Palou J, Baniel J, Klotz L et al. Urothelial carcinoma of the prostate. Urology 69(1 Suppl. ), 50-61 (2007).
83. Steinberg GD, Smith ND, Ryder K, Strangman NM, Slater SJ. Factors affecting valrubicin response in patients with bacillus Calmette-Guèrin- refractory bladder carcinoma in situ. Postgrad. Med. 123(3), 28-34 (2011).
84. Lightfoot AJ, Rosevear HM, O'Donnell MA. Recognition and treatment of BCG failure in bladder cancer. ScientificWorldJournal 11, 602-613 (2011).
85. Yates DR, Rouprêt M. Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy. World J. Urol. 29(4), 415-422 (2011).
86. Gallagher BL, Joudi FN, Maymí JL, O'Donnell MA. Impact of previous bacille Calmette-Guèrin failure pattern on subsequent response to bacille Calmette-Guèrin plus interferon intravesical therapy. Urology 71(2), 297-301 (2008).
87. Oosterlinck W, Solsona E, Akaza H et al. Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. Urology 66 (6 Suppl. 1), 75-89 (2005).
88. Soloway MS. Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder. Urol. Oncol. 24(1), 58-61 (2006).
89. Gofrit ON, Pode D, Lazar A, Katz R, Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur. Urol. 49(2), 303-306; discussion 306 (2006).
90. Pruthi RS, Baldwin N, Bhalani V, Wallen EM. Conservative management of low-risk superficial bladder tumors. J. Urol. 179(1), 87-90; discussion 90 (2008).
91. Hernández V, Alvarez M, de la Peña E et al. Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma. Urology 73(6), 1306-1310 (2009).
92. Donat SM, North A, Dalbagni G, Herr HW. Efficacy of office fulguration for recurrent low-grade papillary bladder tumors less than 0.5 cm. J. Urol. 171(2 Pt 1), 636-639 (2004).
93. Yutkin V, Chin J. Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer. Expert Opin. Investig. Drugs 21(2), 251-260 (2012).